This graph is astonishing. The people that bang on about “natural birth” and “women have been doing this forever without help” need to be forced to stare at this until their eyes water.

No... one... Pipes like gaston Mends stats gripes like gaston No one analyzes genotypes like gaston

Can the #HHS agencies continue to function, given the deep cuts to administrative staff in the recent layoffs? Employees of these agencies are expressing deep fears that so much of the scaffolding is gone that the edifices could crumble. www.statnews.com/2025/04/11/h...

Here is a look at how measles — one of the world’s most infectious viruses — takes over the body.

I think this opinion piece also demonstrates what arguments are likely to be the most convincing to your representative, if they are a Republican

Using data on more than 220,000 individuals on Lyft, researchers report in Science that drivers of color are significantly more likely to receive speeding tickets than white drivers, and to face steeper fines, even when traveling at identical speeds. scim.ag/3QYTjOO

Thrilled to announce that I've joined @kimia-tx.bsky.social as chief technology officer. Kimia's one-of-a-kind chemistry platform is an incredible data engine for building foundation models of chemistry and applying them to dramatically accelerate exploration of small molecule space.

Lungfish xkcd.com/3064

Zeiss has released its light field microscope! zeiss.wistia.com/medias/otnxx...

@kylegriffin1.bsky.social looks like your X account got hacked.

Today, Recursion is announcing a new pre-seed venture fund – the Altitude Lab Fund – to address the #SBIR funding gap hitting early-stage #biotech startups. The fund is backed by Recursion co-founder & CEO Chris Gibson & biotech entrepreneur David Bearss. techcrunch.com/2025/02/19/n...

Proud to see @recursionpharma.bsky.social and Altitude Lab step up to support new translational endeavors in this time of uncertainty for sci funding with the new Altitude Lab Pre-Seed Venture Fund, helping those otherwise waiting on SBIR. See more on @techcrunch.com: techcrunch.com/2025/02/19/n...

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.

Today, Dr. Jan-Karl Burkhardt, MD, MBA, Division Head of Cerebrovascular Surgery at University of Pennsylvania, shared Phase 2 data for REC-994 -- the 1st industry initiated trial in #CCM - in a late-breaking oral presentation at the International Stroke Conference. ir.recursion.com/news-release...

Sometimes the experimental control is messed up – but in a really interesting way! – and it's a great 'night science' trick to make a discovery by recognizing it when it happens.

Well, it's not done up in Millennial Gray, I'll give it that.

I have a new blog devoted to medicinal chemistry in which I will mainly focus on classic papers. My first installment describes the design and discovery of the amazing atorvastatin: a triumph of simple modeling, dogged synthesis and leadership decisions medchemash.substack.com/p/classics-i...

Bluetorial: When the leadership of Science magazine does not seem to care about getting the facts right in a news story... A very troubling incident occurred some years ago and I think the concerns and lessons are important. My apologies for the length, but it is a complicated story.

Small AI-designed proteins neutralized one of cobras' nastiest venom toxins. The findings raise the question: Could AI bring antivenoms into the 21st century? That and more of the best from @science.org and science in this edition of #ScienceAdviser: www.science.org/content/arti... 🧪

Advancing our vision for a virtual cell: In a presentation at #JPM2025, CEO Chris Gibson shared his vision for #TechBio, in which biol & chem datasets & highly predictive ML models, including advanced protein folding, will allow us to build a true virtual cell. ir.recursion.com/static-files...

👉 Read more: ir.recursion.com/news-release...

🔹 Using our AI platform, REC-3565 was designed as a highly selective MALT1 inhibitor that could mitigate potential risks of drug-drug interaction/hyperbilirubinaemia, enhancing its potential in combination therapies. There are ~41k R/R patients w/ CLL & B-cell lymphomas in the US & EU5 annually. 🧵

🔹 Designed & optimized using AI & active learning, REC-4539 is the first reversible LSD1 inhibitor that not only targets peripheral disease but is also designed to penetrate the brain, addressing a critical unmet need. There are ~45k patients with extensive stage SCLC in the US & EU5 annually. 🧵

📣 Big news ahead of JPM: 2 of our key investigational oncology drugs have received regulatory approval to advance to clinical trials: REC-4539 – potential best-in-class LSD1 inhibitor for SCLC & other indications & REC-3565 – a potential best-in-class MALT1 inhibitor for B-cell malignancies. 🧵

Which reminds me, if you have any doubt that our immune systems can use all the help we are able to provide, here is a summary of causes of death in Boston in 1912. Please for the love of your fellow man support antibiotics and vaccination. Source: www.nejm.org/doi/full/10....

Why can a human tolerate a drug that globally inhibits transcription? Why do transcription inhibitors not cure cancer? Our first paper of 2025 may help explain (some) of this! So incredibly proud of @tobiaswilliams.bsky.social & Ewa Michalak who led the work! www.cell.com/molecular-ce...

Amazing, no notes

WOW! "Subtomogram averaging Soluble and membrane-bound complexes ranging in size from >3 MDa to ~200 kDa, including 80S ribosomes, Rubisco, nucleosomes, microtubules, clathrin, photosystem II, and mitochondrial ATP synthase. The majority of these density maps reached sub-nanometer resolution..." 🧪

It's important to distinguish between supporting legal immigration generally and advocating specifically for tech immigration to fill high-skilled jobs. While both positions have merit, they're driven by different motivations and have distinct implications. 1/n

“We should not include plots in scientific papers just to make them aesthetically pleasing. Plots should communicate findings, not decorate.” Good post by @rafalab.bsky.social HT @michaelhoffman.bsky.social

Interviewer: Can you explain this gap on your CV? Chemist: Yeah, that's what's between the HOMO and the LUMO #chemsky

If you work with Python dataframes (pandas, @pola.rs) and are not using skrub.TableReport, you're missing out 😀 We keep improving it

Is Gemini just uniquely stupid?

NEW: Women experiencing pregnancy loss in states with abortion bans told us they wished they had known what to expect and how to advocate for themselves. We created this guide for anyone who finds themselves in the same position. ⤵️

Exciting news! 🚀 The Learning Meaningful Representations of Life ( #LMRL 🌟) workshop is returning at #ICLR2025! 🎉 On 27th / 28th April 2025 in Singapore 🇸🇬, this popular event returns with a fresh organizing team 👇 & bold new ideas 🧠 to explore bridging AI & life sciences 🧬

[email protected] is here now!

Great description by @jeremymberg.bsky.social on the experience of a scientist serving as an expert witness

Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent antibody response against a pathogen. Could lead to topical vaccines that are applied in a cream. @djenetbousbaine.bsky.social led the charge... @natureportfolio.bsky.social 1/55

REC-617 is a testament to the potential of #AI guided precision chemistry & design to deliver new #cancer treatments. Today, we presented the latest interim data for our monotherapy Phase 1 trial for REC-617, a potential best-in-class CDK7 inhibitor, in a live Update Call. 🧵

Dr. Hallett: “Cell cycle dysregulation & transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” Learn more & join the update call 12/10: ir.recursion.com/news-release...

▫️ Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; 🧵

Today at the @theaacr.bsky.social Special Conference in Cancer Research, our CSO David Hallett, PhD shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. Here's what was revealed. 🧵

If you asked them ‘ok but HOW tall is it?’, they’d just say INFINITY. But here it’s not just infinite, but a specific infinite number divided by 4. Let me tell you, people look at you funny if you say something is infinity over 4 tall. alok.github.io/2024/09/28/d...

New blogpost: The ABCs of Alphafold 3, Boltz and Chai-1 blog.booleanbiotech.com/alphafold3-b...

Planning to attend the Superbowl of ML conferences? #NeurIPS (@neuripsconf.bsky.social) is coming to Vancouver Dec. 10-15 & @valenceai.bsky.social will be on site presenting 10+ accepted papers & cohosting a “Night of Science” #TechBio social w/ us & NVIDIA on Thurs. 12/12 👉 RSVP: lu.ma/biikt7ox

Wow! 🤩 This may be the most carefully documented dataset on @polarishq.bsky.social. Great work by @roman-bushuiev.bsky.social! Do I have any #MassSpec researchers in my 🦋 network yet? I would love to hear what you think! github.com/polaris-hub/... #mass #spectrometry #dataset #benchmark

Fascinating thread here: apparently, caffeine and ibuprofen both have binding affinity to their target proteins so weak that they might get tossed out of a typical drug discovery project!

Is there any way to disable new follower notifications in the Android bsky client? Having landed in a starter pack or two, these are now drowning out signal like actual thread replies...

Our combination w/ Exscientia is officially closed & one #TechBio powerhouse has emerged. Our expanded clinical pipeline & partnership programs puts us on par with many mid-sized pharmas but accelerating much faster thanks to our combined AI-enabled platforms. ir.recursion.com/news-release...

Why Recursion Pharmaceuticals abandoned cell painting for brightfield imaging www.owlposting.com/p/why-recurs... After over a decade,Recursion Pharmaceuticals changed its primary assay. Why is that? I answer that question over 5.6k words (26 minutes to read) first journalism-y piece!